A significantly higher proportion of patients achieved an ACR@ at week @ with secukinumab @ mg ( @ -LSB- @ % -RSB- patients ; odds ratio versus placebo @ , @ % CI @-@ ; p < @ ) , @ mg ( @ -LSB- @ % -RSB- patients ; @ , @-@ ; p < @ ) , and @ mg ( @ -LSB- @ % -RSB- patients ; @ , @-@ ; p = @ ) versus placebo ( @ -LSB- @ % -RSB- patients ) .